NCT04700124 · Interventional trial
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
Overall registry status Active not recruiting
Phase 3
Conditions Bladder Cancer
Delaware Valley sites
- MidLantic Urology ( Site 0002) · Bala-Cynwyd, PA · Montgomery County
First posted
Registry updated
Added to the directory